Pérez-Molina JA, Martinez-Perez A, Serre N, Treviño B, Ruiz-Giardín JM, Torrús D, Goikoetxea J, Echevarría EM, Malmierca E, Rojo G, Calabuig E, Gutierrez B, Norman F, Lopez-Velez R.

Characteristics of HIV infected individuals traveling abroad. Results from the plus REDIVI Collaborative Network

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA 2016. 34(2): 108-113. Nº de citas: 5

[doi:10.1016/j.eimc.2015.03.023]

Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC, Terashima A, Samalvides F, Pérez-Molina JA, Plana MN.

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection

The Cochrane database of systematic reviews 2016. (1): . Nº de citas: 108

[doi:10.1002/14651858.CD007745.pub3]

Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feíto M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almirón M, Arribas JR, González-García J, Herranz P.

Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial.

AIDS 2016. 30(1): 75-82. Nº de citas: 8

[doi:10.1097/QAD.0000000000000886]

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

PLOS PATHOGENS 2016. 12(1): . Nº de citas: 31

[doi:10.1371/journal.ppat.1005381]

Monge-Maillo B, López-Vélez R.

Treatment Options for Visceral Leishmaniasis and HIV Coinfection.

AIDS REVIEWS 2016. 18(1): 32-43. Nº de citas: 18

Casado JL, Bañón S, Santiuste C, Serna J, Guzman P, Tenorio M, Liaño F, Rey JM.

Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir

AIDS 2016. 30(2): 231-239. Nº de citas: 26

[doi:10.1097/QAD.0000000000000901]

Casado JL, Mena A, Bañón S, Castro A, Quereda C, Moreno A, Pedreira J, Moreno S.

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis

HIV MEDICINE 2016. 17(1): 62-67. Nº de citas: 4

[doi:10.1111/hiv.12274]

Casado JL, Marín A, Romero V, Bañón S, Moreno A, Perez-Elías MJ, Moreno S, Rodriguez-Sagrado MA.

The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens

HIV MEDICINE 2016. 17(1): 46-55. Nº de citas: 8

[doi:10.1111/hiv.12280]

Corral I, Quereda C, Dronda F, Navas E, Hermida JM, Moreno C, Martínez-San-Millán J.

Progressive multifocal leukoencephalopathy mimicking milliary CNS tuberculosis

JOURNAL OF NEUROVIROLOGY 2015. 21(6, SI): 691-693. Nº de citas: 1

[doi:10.1007/s13365-015-0367-6]

Martínez-Bonet M, Isabel Clemente M, Jesús Serramía M, Muñoz E, Moreno S, Ángeles Muñoz-Fernández M.

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1

SCIENTIFIC REPORTS 2015. 5: 16445-16445. Nº de citas: 31

[doi:10.1038/srep16445]

Casado JL, Bañón S.

Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection

EXPERT REVIEW OF CLINICAL PHARMACOLOGY 2015. 8(6): 709-718. Nº de citas: 4

[doi:10.1586/17512433.2015.1090873]

Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR, NEAT001/ANRS143 Study Group.

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

LANCET HIV 2015. 2(11): 464-473. Nº de citas: 65

[doi:10.1016/S2352-3018(15)00181-2]

Parrondo J, Moreno S, Losa JE, Berenguer J, Martinez-Sesmero JM, Grasset E, Cenoz-Gomis S.

Cost-Utility Analysis of Dolutegravir/Abacavir/Lamivudine (Dtg/Abc/3tc) as a Single Tablet Treatment of Naïve Hiv Infected Patientss.

VALUE IN HEALTH 2015. 18(7): . Nº de citas: 1

[doi:10.1016/j.jval.2015.09.1507]

Rubio-Terrés C, Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Lletí M, Toledo A, Anguita P, Rubio-Rodríguez D, Watt M, Gani R.

Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 2015. 34(11): 2213-2223. Nº de citas: 21

[doi:10.1007/s10096-015-2472-0]

Santos JR, Blanco JL, Masiá M, Gutiérrez F, Pérez-Elías MJ, Iribarren JA, Force L, Antela A, Knobel H, Salavert M, López Bernaldo De Quirós JC, Pino M, Paredes R, Clotet B.

Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2015. 70(11): 3087-3095. Nº de citas: 9

[doi:10.1093/jac/dkv205]

Pérez-Romero P, Bulnes-Ramos A, Torre-Cisneros J, Gavaldá J, Aydillo TA, Moreno A, Montejo M, Fariñas MC, Carratalá J, Muñoz P, Blanes M, Fortún J, Suárez-Benjumea A, López-Medrano F, Barranco JL, Peghin M, Roca C, Lara R, Cordero E, Influenza Vaccine in Solid Organ Transplant Recipient Study Group, Spanish Netwo.

Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe

CLINICAL MICROBIOLOGY AND INFECTION 2015. 21(11): . Nº de citas: 22

[doi:10.1016/j.cmi.2015.07.014]

Martínez-Bonet M, Clemente MI, Álvarez S, Díaz L, García-Alonso D, Muñoz E, Moreno S, Muñoz-Fernández MÁ.

Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal

ANTIVIRAL RESEARCH 2015. 123: 163-171. Nº de citas: 9

[doi:10.1016/j.antiviral.2015.09.014]

Pérez-Molina JA, Perez AM, Norman FF, Monge-Maillo B, López-Vélez R.

Old and new challenges in Chagas disease

LANCET INFECTIOUS DISEASES 2015. 15(11): 1347-1356. Nº de citas: 60

[doi:10.1016/S1473-3099(15)00243-1]